TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancer, today announced the ...
TransCode Therapeutics ( ($RNAZ) ) just unveiled an update. On January 6, 2026, TransCode Therapeutics announced the publication in the Journal of ...
XDA Developers on MSN
Hardware transcoding matters less than you think if you pick the right clients
So long as you choose the right client for the job, your NAS can simply send the file over to the TV, tablet, or streaming ...
To support VIP at true sports scale, we needed a reliable and flexible live-video workflow foundation—in 2025 alone, we ...
Investing.com -- TransCode Therapeutics (NASDAQ:RNAZ) stock surged 18% on Tuesday after the company published preclinical data showing its lead candidate TTX-MC138 demonstrated therapeutic potential ...
BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, ...
Against a backdrop of insatiable demand for compute, Web3 principles and technologies offer enterprises transparent, flexible ...
Publishes Preclinical Data Supporting TTX-MC138 For Glioblastoma. TransCode Therapeutics (NASDAQ: RNAZ) announced the publication of peer-reviewed preclinical research supporting the use of its lead ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a micro-cap biotech company with a market capitalization of just $7.91 million, and Quantum Leap Healthcare Collaborative announced Thursday a ...
(RTTNews) - TransCode Therapeutics, Inc. (RNAZ) and Quantum Leap Healthcare Collaborative, on Friday, announced a collaboration to evaluate TTX-MC138 in a Phase 2a dose-expansion trial. TTX-MC138, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback